Collection

Coronavirus (COVID-19): clinical guidance

Clinical guidance for health and social care professionals.


Documents

Further information

COVID-19 Therapeutic alert: Remdesivir for patients hospitalised with covid update  (15 June 2021) - letter and database entry

Advice from the Medicines and Healthcare Products Regulatory Agency (MHRA) about the Astra Zeneca COVID-19 vaccine thromboembolic events: Letter to healthcare professionals and database entry

Guidance for health professionals and health protection teams can also be found at Health Protection Scotland.

Rapid policy statement – Paliviuzumab for respiratory synctical virus

Update to the interim clinical commissioning policy – Remdesivir

COVID-19 Therapeutic alert: Letter re interim position statement about the use of Tocilizumab for adult patients admitted to ICU with COVID-19 Pneumonia

Interim position statement: Tocilizumab for patients admitted to ICU with COVID-19 pneumonia (adults)

Pfizer BioNTech COVID-19 Vaccine – Doses per Vial (circular)

Pfizer BioNTech COVID-19 Vaccine – Doses per Vial (database)

Information about the use of azithromycin in the management of COVID-19 (circular)

Information about the use of azithromycin in the management of COVID-19 (database)

information about therapeutic anticoagulation (Heparin) in the management of severe COVID-19 (SARS-CoV-2 Positive) patients (circular)

information about therapeutic anticoagulation (Heparin) in the management of severe COVID-19 (SARS-CoV-2 Positive) patients (database)

COVID-19 Therapeutic Alert – Interleukin-6 inhibitors (Tocilizumab or Sarilumab) for adult patients admitted to ICU with COVID-19 pnuemonia (letter).

COVID-19 Therapeutic Alert – Interleukin-6 inhibitors (Tocilizumab or Sarilumab) for adult patients admitted to ICU with COVID-19 pnuemonia (database entry)

AstraZeneca COVID-19 Vaccine - Doses per vial clarification on update to MHRA Information to Healthcare Professionals (letter)

AstraZeneca COVID-19 Vaccine - Doses per vial clarification on update to MHRA Information to Healthcare Professionals (database)

Results from the PRINCIPLE and RECOVERY trials have demonstrated that antimicrobials (azithromycin and doxycycline) are not beneficial in the management of COVID-19 (SARS-CoV-2) positive patients (circular)

Results from the PRINCIPLE and RECOVERY trials have demonstrated that antimicrobials (azithromycin and doxycycline) are not beneficial in the management of COVID-19 (SARS-CoV-2) positive patients (database)

UK Interim Clinical Commissioning Policies have now been published, recommending that two Interleukin-6 (IL-6) inhibitors – tocilizumab and sarilumab - are made available as a treatment option for critically ill adult patients (aged 18 years and over) hospitalised with COVID-19 in accordance with the agreed criteria (alert)

UK Interim Clinical Commissioning Policies have now been published, recommending that two Interleukin-6 (IL-6) inhibitors – tocilizumab and sarilumab - are made available as a treatment option for critically ill adult patients (aged 18 years and over) hospitalised with COVID-19 in accordance with the agreed criteria (database)

Recommendation that colchicine should not be used in the management of COVID-19 positive patients other than in the context of a trial, or unless there is an additional licensed indication for its use (letter)

Recommendation that colchicine should not be used in the management of COVID-19 positive patients other than in the context of a trial, or unless there is an additional licensed indication for its use (database)

COVID-19 therapeutic alert – interleukin-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with covid-19 pneumonia (adults) (letter)

COVID-19 therapeutic alert – Interleukin-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 pneumonia (adults) (database)

Position statement on the use in primary care of in the treatment of inhaled Budesonide For Adults (50 Years And Over)  with COVID-19 (letter)

Position statement on the use in primary care of in the treatment of inhaled Budesonide For Adults (50 Years And Over)  with COVID-19 (database)

Updated UK rapid policy statement circular and database, which extends eligibility for palivizumab beyond the guidance issued by the Joint Committee on Vaccination and Immunisation (JCVI), specifically in the context of the COVID-19 pandemic, which has now been updated to accommodate the atypical current seasonal pattern of infection and increase the maximum number of doses from five to seven (July 2021) circular

Update to the National Institute for Health and Care Excellence (NICE) rapid guideline recommending the consideration of continuous positive airway pressure (CPAP), alongside optimised pharmacological and non-pharmacological management strategies (including body positioning), in patients hospitalised with COVID-19. Read the letter and database entry.

Combined policy replacing previous separately published policies for sarilumab and tocilizumab respectively on 17 February 2021. A single UK Interim Clinical Commissioning Policy has now been published, recommending that equal consideration is given to two potential interleukin-6 (IL-6) inhibitor treatment options - tocilizumab or sarilumab - for adult patients (aged 18 years and older) hospitalised due to COVID-19 in accordance with the agreed criteria. Read the letter and database entry.